

World Journal of *Gastroenterology*

World J Gastroenterol 2024 March 14; 30(10): 1261-1469



EDITORIAL

- 1261 Bridging the gap: Unveiling the crisis of physical inactivity in inflammatory bowel diseases
Stafie R, Singeap AM, Rotaru A, Stanciu C, Trifan A
- 1266 Double role of depression in gastric cancer: As a causative factor and as consequence
Christodoulidis G, Konstantinos-Eleftherios K, Marina-Nektaria K
- 1270 Capsule endoscopy and panendoscopy: A journey to the future of gastrointestinal endoscopy
Rosa B, Cotter J
- 1280 Vonoprazan-amoxicillin dual regimen with *Saccharomyces boulardii* as a rescue therapy for *Helicobacter pylori*: Current perspectives and implications
Dirjayanto VJ, Audrey J, Simadibrata DM
- 1287 Women health and microbiota: Different aspects of well-being
Nannini G, Amedei A
- 1291 Nomograms and prognosis for superficial esophageal squamous cell carcinoma
Lin HT, Abdelbaki A, Krishna SG

REVIEW

- 1295 Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies
Ma H, Yan QZ, Ma JR, Li DF, Yang JL
- 1313 Optimizing nutrition in hepatic cirrhosis: A comprehensive assessment and care approach
Mendez-Guerrero O, Carranza-Carrasco A, Chi-Cervera LA, Torre A, Navarro-Alvarez N
- 1329 Optimizing prediction models for pancreatic fistula after pancreatectomy: Current status and future perspectives
Yang F, Windsor JA, Fu DL

ORIGINAL ARTICLE

Retrospective Cohort Study

- 1346 Cumulative effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease in China
Chen JF, Wu ZQ, Liu HS, Yan S, Wang YX, Xing M, Song XQ, Ding SY
- 1358 Time trends and outcomes of gastrostomy placement in a Swedish national cohort over two decades
Skogar ML, Sundbom M

Retrospective Study

- 1368 Stage at diagnosis of colorectal cancer through diagnostic route: Who should be screened?

Agatsuma N, Utsumi T, Nishikawa Y, Horimatsu T, Seta T, Yamashita Y, Tanaka Y, Inoue T, Nakanishi Y, Shimizu T, Ohno M, Fukushima A, Nakayama T, Seno H

Observational Study

- 1377 Differential diagnosis of Crohn's disease and intestinal tuberculosis based on ATR-FTIR spectroscopy combined with machine learning

Li YP, Lu TY, Huang FR, Zhang WM, Chen ZQ, Guang PW, Deng LY, Yang XH

Prospective Study

- 1393 Establishment and validation of an adherence prediction system for lifestyle interventions in non-alcoholic fatty liver disease

Zeng MH, Shi QY, Xu L, Mi YQ

Basic Study

- 1405 Alkaline sphingomyelinase deficiency impairs intestinal mucosal barrier integrity and reduces antioxidant capacity in dextran sulfate sodium-induced colitis

Tian Y, Li X, Wang X, Pei ST, Pan HX, Cheng YQ, Li YC, Cao WT, Petersen JDD, Zhang P

- 1420 Preliminary exploration of animal models of congenital choledochal cysts

Zhang SH, Zhang YB, Cai DT, Pan T, Chen K, Jin Y, Luo WJ, Huang ZW, Chen QJ, Gao ZG

- 1431 Serotonin receptor 2B induces visceral hyperalgesia in rat model and patients with diarrhea-predominant irritable bowel syndrome

Li ZY, Mao YQ, Hua Q, Sun YH, Wang HY, Ye XG, Hu JX, Wang YJ, Jiang M

META-ANALYSIS

- 1450 Shear-wave elastography to predict hepatocellular carcinoma after hepatitis C virus eradication: A systematic review and meta-analysis

Esposito G, Santini P, Galasso L, Mignini I, Ainora ME, Gasbarrini A, Zocco MA

LETTER TO THE EDITOR

- 1461 Current considerations on intraductal papillary neoplasms of the bile duct and pancreatic duct

Pavlidis ET, Galanis IN, Pavlidis TE

- 1466 Are we ready to use new endoscopic scores for ulcerative colitis?

Quera R, Núñez F P

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Toru Mizuguchi, MD, PhD, Professor, Surgeon, Department of Nursing, Division of Surgical Science, Sapporo Medical University Postgraduate School of Health Science, Sapporo, Hokkaido 0608556, Japan. tmizu@sapmed.ac.jp

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG's CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Ying-Yi Yuan; **Production Department Director:** Xiang Li; **Cover Editor:** Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu (Biliary Tract Disease)

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

March 14, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University
Biliary Tract Disease Institute, Fudan University

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

POLICY OF CO-AUTHORS

<https://www.wjgnet.com/bpg/GerInfo/310>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER's OFFICIAL WEBSITE

<https://www.shca.org.cn>
<https://www.zs-hospital.sh.cn>



Vonoprazan-amoxicillin dual regimen with *Saccharomyces boulardii* as a rescue therapy for *Helicobacter pylori*: Current perspectives and implications

Valerie Josephine Dirjayanto, Jessica Audrey, Daniel Martin Simadibrata

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Oka A, Japan

Received: December 23, 2023

Peer-review started: December 23, 2023

First decision: January 13, 2024

Revised: January 22, 2024

Accepted: February 21, 2024

Article in press: February 21, 2024

Published online: March 14, 2024



Valerie Josephine Dirjayanto, Jessica Audrey, Faculty of Medicine, Universitas Indonesia, Jakarta Pusat 10430, DKI Jakarta, Indonesia

Daniel Martin Simadibrata, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, United States

Daniel Martin Simadibrata, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, United Kingdom

Corresponding author: Daniel Martin Simadibrata, MD, MSc, Postdoctoral Fellow, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St. SW, Rochester, Minnesota 55905, United States. simadibrata.daniel@mayo.edu

Abstract

Yu *et al*'s study in the *World Journal of Gastroenterology* (2023) introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with *Saccharomyces boulardii* (*S. boulardii*) for the rescue therapy against *Helicobacter pylori* (*H. pylori*), a pathogen responsible for peptic ulcers and gastric cancer. Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression, which is minimally affected by mealtime. Compared to proton pump inhibitors, which bind irreversibly to cysteine residues in the H⁺/K⁺-ATPase pump, Vonoprazan competes with the K⁺ ions, prevents the ions from binding to the pump and blocks acid secretion. Concerns with increasing antibiotic resistance, effects on the gut microbiota, patient compliance, and side effects have led to the advent of a dual regimen for *H. pylori*. Previous studies suggested that *S. boulardii* plays a role in stabilizing the gut barrier which improves *H. pylori* eradication rate. With an acceptable safety profile, the dual-adjunct regimen was effective regardless of prior treatment failure and antibiotic resistance profile, thereby strengthening the applicability in clinical settings. Nonetheless, *S. boulardii* comes in various formulations and dosages, warranting further exploration into the optimal dosage for supplementation in rescue therapy. Additionally, larger, randomized, double-blinded controlled trials are warranted to confirm these promising results.

Key Words: Vonoprazan; *Saccharomyces boulardii*; *Helicobacter pylori*; Rescue therapy; Eradication rate

Core Tip: Vonoprazan-amoxicillin dual therapy with *Saccharomyces boulardii* (*S. boulardii*, VAS regimen) emerges as a novel rescue therapy for eradicating *Helicobacter pylori* (*H. pylori*). Vonoprazan, a potassium-competitive acid blocker, exhibits superior acid suppression compared to proton pump inhibitors. Notably, dual therapy minimizes the use of an additional antibiotic while maintaining efficacy comparable to traditional triple therapy. This paper highlights the role of *S. boulardii*, a probiotic, in enhancing the efficacy of Vonoprazan dual therapy by restoring gut microbiota balance, directly affecting *H. pylori*, and regulating immunomodulation. The VAS regimen emerges as a promising treatment alternative, demonstrating remarkable eradication of *H. pylori*, even in triple-resistant strains.

Citation: Dirjayanto VJ, Audrey J, Simadibrata DM. Vonoprazan-amoxicillin dual regimen with *Saccharomyces boulardii* as a rescue therapy for *Helicobacter pylori*: Current perspectives and implications. *World J Gastroenterol* 2024; 30(10): 1280-1286

URL: <https://www.wjgnet.com/1007-9327/full/v30/i10/1280.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v30.i10.1280>

INTRODUCTION

Yu *et al*'s study introduced a novel regimen involving vonoprazan-amoxicillin dual therapy with *Saccharomyces boulardii* (*S. boulardii*) for the rescue therapy against *Helicobacter pylori* (*H. pylori*), a critical pathogen responsible for gastroduodenal diseases including peptic ulcers and gastric cancer[1]. First approved in Japan in 2014, vonoprazan is a potassium-competitive acid blocker renowned for its profound acid suppression, which is minimally affected by mealtime[2]. The target of action for vonoprazan is the $H^+/K^+-ATPase$, a proton pump that becomes activated when it gets inserted into the canalicular membrane to secrete acid (H^+) from the gastric parietal cells into the lumen[3]. The current first-line treatment regimen for *H. pylori* eradication includes a standard triple therapy with proton pump inhibitors (PPIs) and two antibiotics. PPIs are prodrugs that are activated in an acidic (low pH) environment and work by irreversibly binding to the cysteine residue on the $H^+/K^+-ATPase$ pump. On the other hand, vonoprazan works independently of the pH level and competes with the K^+ ions, preventing the ions from binding to the pump and, therefore, blocking acid (H^+) secretion [4]. Due to the high negative logarithm of the acid dissociation constant (pKa), vonoprazan quickly accumulates in gastric tissue and has delayed clearance once bound to $H^+/K^+-ATPase$. This property allows vonoprazan to offer a more rapid and longer-lasting gastric acid suppression than the PPIs. In fact, compared to lansoprazole, vonoprazan resulted in a significantly greater 24-hour holding-time ratio for intragastric pH > 4 on days 1 and 7[3]. Therefore, the superior acid suppression properties of vonoprazan, compared to PPIs, highly attract its potential use for treating gastric acid-related disease[5].

VONOPRAZAN DUAL THERAPY REGIMEN: BREAKTHROUGH AND EVIDENCE

Dual therapy against *H. pylori* is a relatively new treatment regimen approach. Previously, the standard triple therapy containing PPIs, Clarithromycin, and Amoxicillin or Metronidazole was the mainstay treatment for *H. pylori* eradication. However, antibiotic resistance has caused the eradication rate to diminish (< 80%)[6]. In fact, resistance to clarithromycin has continuously increased, with reports in Japan describing an increase from 7% to 28.5% over the course of 14 years[7] and in Australia suggesting an increase of 3.7% annually over the past 20 years[8]. In the United States, eradication rates of triple therapy with PPI have declined to less than 80%, attributable to both antibiotic resistance and failure to maintain the intragastric pH required for effective antimicrobial activity[9].

Yu *et al*'s prospective single-arm trial in the *World Journal of Gastroenterology* introduced a novel regimen involving vonoprazan-amoxicillin dual therapy with the addition of *S. boulardii* (VAS regimen) for the rescue therapy against *H. pylori* in patients with a history of treatment failure[1]. In this study, the resistance of *H. pylori* to clarithromycin, metronidazole, and levofloxacin was 91.3%, 100%, and 60.9%, respectively. Overall, the eradication rate of *H. pylori* was 92.6% (63/68). Interestingly, out of the patients with triple-resistant *H. pylori* (60.9%; $n = 14/23$), a 92.9% eradication rate was achieved with the vonoprazan-based rescue therapy. This suggested that such a regimen was effective and safe regardless of antibiotic resistance.

Previous studies investigating treatment-naïve patients showed promising findings for Vonoprazan dual therapy. In Chey *et al*'s phase 3 randomized controlled trial (RCT), the reported eradication rate for clarithromycin-resistant *H. pylori* with Vonoprazan-Amoxicillin dual therapy was 69.6%, while eradication rates were 65.8% with vonoprazan-amoxicillin-clarithromycin triple therapy and 31.9% with Lansoprazole triple therapy[9]. Despite not reaching values above 90%, the eradication rate was numerically higher in the dual therapy, suggesting that adding Clarithromycin may be unnecessary in treating clarithromycin-resistant strains. Zuberi *et al*'s study reported that the vonoprazan-based regimen was superior to the PPI triple therapy regimen in eradicating *H. pylori* (93.5% vs 83.9%)[10]. Similarly, Liu *et al*'s network meta-analysis suggested that vonoprazan-based therapies were significantly more effective in eradicating *H. pylori* than PPI triple therapy, with the best safety profile shown by the vonoprazan dual therapy[11]. Therefore, vonoprazan dual therapy

presents as a lower-cost, simple, yet effective treatment option for *H. pylori* eradication.

As for patients with a history of two treatment failures, vonoprazan-based triple therapy yielded a significantly higher success rate in comparison to esomeprazole-based therapy[12]. Similarly, for third-line therapy, the eradication rate with the vonoprazan-amoxicillin-sitafloxacin regimen was higher than the PPI-based regimen (75.8% *vs* 53.3%), despite no significant difference in the intention-to-treat analyses ($P = 0.071$)[13]. The duration of therapy might explain the insignificant difference in eradication rates since Sue *et al*[13] had prescribed the treatment regimens for only seven days, whereas Yu *et al*[1] provided the regimen for 14 d. Therefore, although no study has investigated the effect of therapy duration on eradication rates, available data suggest that long-term regimens may be more effective.

SACCHAROMYCES BOULARDII AS AN ADJUNCT THERAPY IN *H. PYLORI* ERADICATION

The use of antibiotics in treatment regimens for eradicating *H. pylori* has been shown to disrupt the balance of gut microbiota and may elicit adverse events. Recent studies have shown that probiotics, including *S. boulardii*, may contribute to mitigating these effects by: (1) Maintaining the balance and integrity of the normal gut microbiota; (2) direct activity against the pathogenesis of *H. pylori*; and (3) immunomodulation (Figure 1)[14]. In the context of therapy, Keikha and Kamali[14] investigated the addition of *S. boulardii* to the standard triple regimen, and the addition of *S. boulardii* was shown to be associated with a lower proportion of anaerobic bacteria, including *Bacteroides* and *Clostridium*, as well as higher proportion of commensal bacteria including *Bifidobacterium* and *Lactobacillus*[14]. Sakarya and Gunay[15] *in vivo* study proved that *S. boulardii* may also directly contribute to the eradication of *H. pylori* via the $\alpha 2,3$ -linked sialic acid-selective neuraminidase activity, leading to reduced adhesion to host cells. Additionally, *S. boulardii* may produce proteins that modulate cytokines, contribute to the activation of peroxisome proliferator-activated receptor- γ , and trigger antibody production, leading to an anti-inflammatory effect that sustains the gastrointestinal system[16].




Figure 1 Mechanism of action of *Saccharomyces boulardii* in *Helicobacter pylori* eradication. *H. pylori*: *Helicobacter pylori*.

Yu *et al*[1] were the first to investigate the combination of a vonoprazan dual regimen with *S. boulardii* as an adjunct therapy, providing new insights into its efficacy in rescue therapy. This data builds on previous studies investigating the addition of *S. boulardii* for standard triple or quadruple therapy. Qu *et al*[17] provided a two-stage intervention for rescue therapy, during which the patients were administered *S. boulardii* as monotherapy for two weeks, followed by bismuth quadruple therapy if required. The eradication rates in patients receiving *S. boulardii* were reported to be higher than those who did not receive *S. boulardii*, thus supporting its effectiveness. However, several other studies, including Zojaji *et al*[18], did not show any significant improvement in eradication with the addition of *S. boulardii*; however, it was noted that the side effects, including nausea, bloating, and diarrhea, were lower. In addition, a meta-analysis by Liu *et al*[11] investigating *S. boulardii* in addition to standard triple therapy suggested that it yielded beneficial outcomes in eradication, the occurrence of adverse effects, and symptom reduction. Another meta-analysis of 18 RCTs by Zhou *et al*[19] demonstrated a slight pooled improvement in the eradication rate by 9% while decreasing the adverse effects by half. Therefore, while the effectiveness of adding *S. boulardii* for eradicating *H. pylori* might be modest, the reduction of adverse effects makes it worthwhile for this probiotic to be added to the regimen.

FACTORS AFFECTING TREATMENT FAILURE OF THE VONOPRAZAN-AMOXICILLIN- *S. BOULARDII*

Demographic factors such as age, gender, smoking history, and alcohol consumption were not associated with the VAS treatment regimen failure in Yu *et al*[1] study. Several socio-demographic characteristics, such as gender and areas of residence, have been significantly associated with *H. pylori* eradication failure[20] despite inconsistent results observed across studies[21,22]. This suggests that the impact of socioeconomic and demographic factors on treatment outcomes may vary across different patient populations. Such variations may stem from differences in antibiotic usage patterns, antimicrobial resistance, and medication adherence[23-25].

It is interesting to note that anxiety was identified as a risk factor for treatment failure with the VAS treatment regimen. This finding aligns with previous research linking psychological factors to dyspeptic symptoms. For instance, patients with disorders of the gut-brain interaction were noted to have higher rates of anxiety and depression[26]. This relationship may be correlated to the intricate brain-gut axis, a circuit linking the central, peripheral, and autonomic nervous systems with gastrointestinal functions. Gut microorganisms, including *H. pylori* infection, were hypothesized to interact with this axis, as evident by the observation that stress and emotional disorders negatively impact intestinal flora and digestive function[27]. Further investigations suggest that this relationship may be bidirectional. *H. pylori* infection was associated with altered eating behavior, anxiety and depression-like behaviors, cognitive dysfunction, and lower pain thresholds[27-29]. On the other hand, a study in mice models by Guo *et al*[30] demonstrated that the induction of psychological stress significantly increased *H. pylori* colonization and was associated with more extensive gastric mucosal injury. The underlying mechanisms of altered brain-gut axis potentially involve direct neurotoxic effects, activation of proinflammatory responses, and micronutrient deficiencies, areas which are still highly subject to research[27]. The complex interplay between psychological disorders and *H. pylori* infection underscores the importance of psychological assessments and interventions, such as cognitive behavioral therapy or counseling sessions, to enhance treatment success in *H. pylori* infections[31,32].

Notably, Yu *et al*[1] also showed that the number of previous treatment failures was not associated with treatment failure in this VAS regimen. Eradication rates were consistently high, irrespective of resistance to clarithromycin and levofloxacin. This is in contrast to a prior study that identified any prior exposure to antibiotics as a risk factor for treatment failure with a clarithromycin-containing triple therapy regimen[33]. Clarithromycin resistance was shown to be associated with Metronidazole resistance[34], leading to the prevalence of double-resistant strains, particularly in individuals who had previously failed two eradication treatments[35-38]. Furthermore, sufficient acid inhibition is required for successful *H. pylori* eradication, as it influences the stability and bioavailability of some antibiotics, including amoxicillin. Eradication failure was often observed in patients who are extensive CYP2C19 metabolizers of PPI, as they exhibit rapid PPI inactivation and insufficient acid suppression[39,40]. Vonoprazan exhibits stronger and longer acid suppression than PPI[41], which may explain the significant superiority of a vonoprazan-based regimen over PPI-based therapy regarding *H. pylori* eradication success[42]. This suggests the potential use of the VAS regimen as a rescue therapy for *H. pylori* infections resistant to other essential antibiotics, particularly in the context of increasing global antimicrobial resistance.

SAFETY PROFILE OF VONOPRAZAN-BASED THERAPIES

The impact of adverse events on therapy discontinuation and treatment adherence is a critical aspect of any treatment regimen. In Yu *et al*'s study[1], the VAS regimen exhibited a low rate of adverse events, all of which were reported as mild or moderate. The safety profile of vonoprazan, as reported in numerous clinical studies, consistently demonstrates its superiority or, at the very least, equivalence to that of PPIs. A meta-analysis of RCTs demonstrated a significantly lower rate of adverse events with vonoprazan-based triple therapy (32.7%) compared to PPI-based triple therapy (40.5%) while maintaining a higher efficacy in terms of *H. pylori* eradication rate[43].

Commonly reported adverse events include diarrhea, dysgeusia, loose stool, and skin eruption[44]. While Suzuki *et al* [45] noted a slightly higher incidence of skin rash in vonoprazan-based therapy, it is noteworthy that the vonoprazan-based regimen was generally well-tolerated, and no instances of therapy discontinuation occurred due to the adverse events.

CONCLUSION

The superiority of the vonoprazan-based regimen in terms of both efficacy and safety highlights its potential as an excellent alternative for *H. pylori* treatment and positions it as an effective option for rescue therapy. Notably, the vonoprazan-amoxicillin dual therapy has exhibited acceptable efficacy in *H. pylori* eradication, comparable to the outcomes of vonoprazan-based triple therapy. Given the increasing rates of clarithromycin resistance in various geographical regions, adding clarithromycin to vonoprazan and amoxicillin may only offer a marginal benefit. The dual regimen minimizes the use of an unnecessary additional antibiotic while maintaining efficacy similar to that of triple therapy, a crucial consideration amid the current surge in antibiotic resistance[46]. Additionally, the supplementation of *S. boulardii* as an adjunct therapy to vonoprazan-based regimens has shown positive effects on *H. pylori* eradication and reduced adverse events, possibly attributed to the maintenance of normal gut microbiota.

However, it is essential to acknowledge certain limitations in this study. While this study supported the efficacy of a dual vonoprazan-based regimen with the addition of *S. boulardii* for rescue therapy, it should be noted that the number of study participants is considered small. Additionally, the generalizability of the reduction of adverse events seen with the addition of *S. boulardii* might be limited since different populations possess different gut microbiota, which is affected by geography and dietary habits[47]. Given the various formulations and dosages available, further exploration is needed to determine the optimal dosing of *S. boulardii* supplementation in such rescue therapy. Lastly, as this study employed a single-arm design, direct comparisons of the VAS regimen to currently recommended regimens are lacking. Therefore, randomized double-blinded controlled trials with large sample sizes are required to validate these promising results.

FOOTNOTES

Author contributions: Dirjayanto VJ, Audrey J, and Simadibrata DM reviewed the literature, drafted the original manuscript, and critically revised the manuscript for important intellectual content; all authors have read and approved the final version of the manuscript.

Conflict-of-interest statement: All authors have no conflict of interest to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: United States

ORCID number: Valerie Josephine Dirjayanto 0000-0003-4170-7742; Jessica Audrey 0000-0003-3329-8651; Daniel Martin Simadibrata 0000-0002-7512-2112.

S-Editor: Lin C

L-Editor: A

P-Editor: Zhao YQ

REFERENCES

- 1 Yu J, Lv YM, Yang P, Jiang YZ, Qin XR, Wang XY. Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection. *World J Gastroenterol* 2023; **29**: 3133-3144 [PMID: 37346155 DOI: 10.3748/wjg.v29.i20.3133]
- 2 Garnock-Jones KP. Vonoprazan: first global approval. *Drugs* 2015; **75**: 439-443 [PMID: 25744862 DOI: 10.1007/s40265-015-0368-z]
- 3 Laine L, Sharma P, Mulford DJ, Hunt B, Leifke E, Smith N, Howden CW. Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects. *Am J Gastroenterol* 2022; **117**: 1158-1161 [PMID: 35294415 DOI: 10.14309/ajg.0000000000001735]
- 4 Luo HJ, Deng WQ, Zou K. Protonated form: the potent form of potassium-competitive acid blockers. *PLoS One* 2014; **9**: e97688 [PMID: 24845980 DOI: 10.1371/journal.pone.0097688]
- 5 Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. *Therap Adv Gastroenterol* 2018; **11**: 1756283X17745776 [PMID: 29383028 DOI: 10.1177/1756283X17745776]
- 6 Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. *World J Clin Cases* 2022; **10**: 6349-6359 [PMID: 35979311 DOI: 10.12998/wjcc.v10.i19.6349]
- 7 Okamura T, Suga T, Nagaya T, Arakura N, Matsumoto T, Nakayama Y, Tanaka E. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. *Helicobacter* 2014; **19**: 214-220 [PMID: 24758533 DOI: 10.1111/hel.12124]
- 8 Schubert JP, Warner MS, Rayner CK, Roberts-Thomson IC, Mangoni AA, Costello S, Bryant RV. Increasing Helicobacter pylori clarithromycin resistance in Australia over 20 years. *Intern Med J* 2022; **52**: 1554-1560 [PMID: 34865299 DOI: 10.1111/imj.15640]
- 9 Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. *Gastroenterology* 2022; **163**: 608-619 [PMID: 35679950 DOI: 10.1053/j.gastro.2022.05.055]
- 10 Zuberi BF, Ali FS, Rasheed T, Bader N, Hussain SM, Saleem A. Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial. *Pak J Med Sci* 2022; **38**: 965-969 [PMID: 35634610 DOI: 10.12669/pjms.38.4.5436]
- 11 Liu L, Li F, Shi H, Nahata MC. The Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis. *Antibiotics (Basel)* 2023; **12** [PMID: 36830257 DOI: 10.3390/antibiotics12020346]
- 12 Saito Y, Konno K, Sato M, Nakano M, Kato Y, Saito H, Serizawa H. Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori. *Cancers (Basel)* 2019; **11** [PMID: 30669474 DOI: 10.3390/cancers11010116]
- 13 Sue S, Shibata W, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S. Randomized trial of vonoprazan-based vs proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. *J Gastroenterol Hepatol* 2019; **34**: 686-692 [PMID: 30151994 DOI: 10.1111/jgh.14456]
- 14 Keikha M, Kamali H. The impact of Saccharomyces boulardii adjuvant supplementation on alternation of gut microbiota after H. pylori

- eradication; a metagenomics analysis. *Gene Rep* 2022; **26**: 101499 [DOI: [10.1016/j.genrep.2022.101499](https://doi.org/10.1016/j.genrep.2022.101499)]
- 15 **Sakarya S**, Gunay N. Saccharomyces bouldarii expresses neuraminidase activity selective for α ,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. *APMIS* 2014; **122**: 941-950 [PMID: [24628732](https://pubmed.ncbi.nlm.nih.gov/24628732/) DOI: [10.1111/apm.12237](https://doi.org/10.1111/apm.12237)]
 - 16 **Pothoulakis C**. Review article: anti-inflammatory mechanisms of action of Saccharomyces bouldarii. *Aliment Pharmacol Ther* 2009; **30**: 826-833 [PMID: [19706150](https://pubmed.ncbi.nlm.nih.gov/19706150/) DOI: [10.1111/j.1365-2036.2009.04102.x](https://doi.org/10.1111/j.1365-2036.2009.04102.x)]
 - 17 **Qu P**, Liu X, Xia X, Xie X, Luo J, Cheng S, Chi J, Liu P, Li H, Zhao W, Yang H, Xu C. Saccharomyces bouldarii Allows Partial Patients to Avoid Reusing Bismuth Quadruple for Helicobacter pylori Rescue Therapy: A Single-Center Randomized Controlled Study. *Front Cell Infect Microbiol* 2022; **12**: 903002 [PMID: [35880079](https://pubmed.ncbi.nlm.nih.gov/35880079/) DOI: [10.3389/fcimb.2022.903002](https://doi.org/10.3389/fcimb.2022.903002)]
 - 18 **Zojaji H**, Ghobakhlou M, Rajabalinia H, Ataei E, Jahani Sherafat S, Moghimi-Dehkordi B, Bahreiny R. The efficacy and safety of adding the probiotic Saccharomyces bouldarii to standard triple therapy for eradication of H.pylori: a randomized controlled trial. *Gastroenterol Hepatol Bed Bench* 2013; **6**: S99-S104 [PMID: [24834296](https://pubmed.ncbi.nlm.nih.gov/24834296/)]
 - 19 **Zhou BG**, Chen LX, Li B, Wan LY, Ai YW. Saccharomyces bouldarii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. *Helicobacter* 2019; **24**: e12651 [PMID: [31414551](https://pubmed.ncbi.nlm.nih.gov/31414551/) DOI: [10.1111/hel.12651](https://doi.org/10.1111/hel.12651)]
 - 20 **Peña-Galo E**, Gotor J, Harb Y, Alonso M, Alcedo J. Socioeconomic and demographic factors associated with failure in Helicobacter pylori eradication using the standard triple therapy. *Gastroenterol Hepatol Bed Bench* 2021; **14**: 53-58 [PMID: [33868610](https://pubmed.ncbi.nlm.nih.gov/33868610/)]
 - 21 **Smith S**, Jolaiya T, Fowora M, Palamides P, Ngoka F, Bamidele M, Lesi O, Onyekwere C, Ugiagbe R, Agbo I, Ndububa D, Adekanle O, Adedeji A, Adeleye I, Harrison U. Clinical and Socio- Demographic Risk Factors for Acquisition of Helicobacter pylori Infection in Nigeria. *Asian Pac J Cancer Prev* 2018; **19**: 1851-1857 [PMID: [30049197](https://pubmed.ncbi.nlm.nih.gov/30049197/) DOI: [10.22034/APJCP.2018.19.7.1851](https://doi.org/10.22034/APJCP.2018.19.7.1851)]
 - 22 **Gebeyehu E**, Nigatu D, Engidawork E. Helicobacter pylori eradication rate of standard triple therapy and factors affecting eradication rate at Bahir Dar city administration, Northwest Ethiopia: A prospective follow up study. *PLoS One* 2019; **14**: e0217645 [PMID: [31163069](https://pubmed.ncbi.nlm.nih.gov/31163069/) DOI: [10.1371/journal.pone.0217645](https://doi.org/10.1371/journal.pone.0217645)]
 - 23 **Nayar DS**. Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area. *Infect Drug Resist* 2018; **11**: 205-211 [PMID: [29430191](https://pubmed.ncbi.nlm.nih.gov/29430191/) DOI: [10.2147/IDR.S153617](https://doi.org/10.2147/IDR.S153617)]
 - 24 **Lim SG**, Park RW, Shin SJ, Yoon D, Kang JK, Hwang JC, Kim SS, Kim JH, Lee KM. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. *Dig Liver Dis* 2016; **48**: 385-390 [PMID: [26856963](https://pubmed.ncbi.nlm.nih.gov/26856963/) DOI: [10.1016/j.dld.2015.12.001](https://doi.org/10.1016/j.dld.2015.12.001)]
 - 25 **Lefebvre M**, Chang HJ, Morse A, van Zanten SV, Goodman KJ, CANHelp Working Group. Adherence and barriers to H. pylori treatment in Arctic Canada. *Int J Circumpolar Health* 2013; **72**: 22791 [PMID: [24416723](https://pubmed.ncbi.nlm.nih.gov/24416723/) DOI: [10.3402/ijch.v72i0.22791](https://doi.org/10.3402/ijch.v72i0.22791)]
 - 26 **Xiong RG**, Li J, Cheng J, Zhou DD, Wu SX, Huang SY, Saimaiti A, Yang ZJ, Gan RY, Li HB. The Role of Gut Microbiota in Anxiety, Depression, and Other Mental Disorders as Well as the Protective Effects of Dietary Components. *Nutrients* 2023; **15** [PMID: [37513676](https://pubmed.ncbi.nlm.nih.gov/37513676/) DOI: [10.3390/nu15143258](https://doi.org/10.3390/nu15143258)]
 - 27 **Budzyński J**, Kłopotka M. Brain-gut axis in the pathogenesis of Helicobacter pylori infection. *World J Gastroenterol* 2014; **20**: 5212-5225 [PMID: [24833851](https://pubmed.ncbi.nlm.nih.gov/24833851/) DOI: [10.3748/wjg.v20.i18.5212](https://doi.org/10.3748/wjg.v20.i18.5212)]
 - 28 **Bercik P**, Verdú EF, Foster JA, Lu J, Scharringa A, Kean I, Wang L, Blennerhassett P, Collins SM. Role of gut-brain axis in persistent abnormal feeding behavior in mice following eradication of Helicobacter pylori infection. *Am J Physiol Regul Integr Comp Physiol* 2009; **296**: R587-R594 [PMID: [19129375](https://pubmed.ncbi.nlm.nih.gov/19129375/) DOI: [10.1152/ajpregu.90752.2008](https://doi.org/10.1152/ajpregu.90752.2008)]
 - 29 **Gorlé N**, Bauwens E, Haesebrouck F, Smet A, Vandenbroucke RE. Helicobacter and the Potential Role in Neurological Disorders: There Is More Than Helicobacter pylori. *Front Immunol* 2020; **11**: 584165 [PMID: [33633723](https://pubmed.ncbi.nlm.nih.gov/33633723/) DOI: [10.3389/fimmu.2020.584165](https://doi.org/10.3389/fimmu.2020.584165)]
 - 30 **Guo G**, Jia KR, Shi Y, Liu XF, Liu KY, Qi W, Guo Y, Zhang WJ, Wang T, Xiao B, Zou QM. Psychological stress enhances the colonization of the stomach by Helicobacter pylori in the BALB/c mouse. *Stress* 2009; **12**: 478-485 [PMID: [20102319](https://pubmed.ncbi.nlm.nih.gov/20102319/) DOI: [10.3109/10253890802642188](https://doi.org/10.3109/10253890802642188)]
 - 31 **Kabeer KK**, Ananthakrishnan N, Anand C, Balasundaram S. Prevalence of Helicobacter Pylori Infection and Stress, Anxiety or Depression in Functional Dyspepsia and Outcome after Appropriate Intervention. *J Clin Diagn Res* 2017; **11**: VC11-VC15 [PMID: [28969250](https://pubmed.ncbi.nlm.nih.gov/28969250/) DOI: [10.7860/JCDR/2017/26745.10486](https://doi.org/10.7860/JCDR/2017/26745.10486)]
 - 32 **Haag S**, Senf W, Tagay S, Langkafel M, Braun-Lang U, Pietsch A, Heuft G, Talley NJ, Holtmann G. Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy? *Aliment Pharmacol Ther* 2007; **25**: 973-986 [PMID: [17403002](https://pubmed.ncbi.nlm.nih.gov/17403002/) DOI: [10.1111/j.1365-2036.2007.03277.x](https://doi.org/10.1111/j.1365-2036.2007.03277.x)]
 - 33 **Guo CG**, Jiang F, Cheung KS, Li B, Ooi PH, Leung WK. Timing of prior exposure to antibiotics and failure of Helicobacter pylori eradication: a population-based study. *J Antimicrob Chemother* 2022; **77**: 517-523 [PMID: [34791274](https://pubmed.ncbi.nlm.nih.gov/34791274/) DOI: [10.1093/jac/dkab415](https://doi.org/10.1093/jac/dkab415)]
 - 34 **Heep M**, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. *Eur J Clin Microbiol Infect Dis* 2000; **19**: 538-541 [PMID: [10968325](https://pubmed.ncbi.nlm.nih.gov/10968325/) DOI: [10.1007/s100960000288](https://doi.org/10.1007/s100960000288)]
 - 35 **Mégraud F**. H pylori antibiotic resistance: prevalence, importance, and advances in testing. *Gut* 2004; **53**: 1374-1384 [PMID: [15306603](https://pubmed.ncbi.nlm.nih.gov/15306603/) DOI: [10.1136/gut.2003.022111](https://doi.org/10.1136/gut.2003.022111)]
 - 36 **Gisbert JP**. "Rescue" regimens after Helicobacter pylori treatment failure. *World J Gastroenterol* 2008; **14**: 5385-5402 [PMID: [18803350](https://pubmed.ncbi.nlm.nih.gov/18803350/) DOI: [10.3748/wjg.14.5385](https://doi.org/10.3748/wjg.14.5385)]
 - 37 **Cammarota G**, Martino A, Pirozzi G, Cianci R, Branca G, Nista EC, Cazzato A, Cannizzaro O, Miele L, Grieco A, Gasbarrini A, Gasbarrini G. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. *Aliment Pharmacol Ther* 2004; **19**: 789-795 [PMID: [15043520](https://pubmed.ncbi.nlm.nih.gov/15043520/) DOI: [10.1111/j.1365-2036.2004.01910.x](https://doi.org/10.1111/j.1365-2036.2004.01910.x)]
 - 38 **Hwang JY**, Kim C, Kwon YH, Lee JE, Jeon SW, Nam SY, Seo AN, Han MH, Park JH. Dual Clarithromycin and Metronidazole Resistance Is the Main Cause of Failure in Ultimate Helicobacter pylori Eradication. *Dig Dis* 2021; **39**: 451-461 [PMID: [33429397](https://pubmed.ncbi.nlm.nih.gov/33429397/) DOI: [10.1159/000514278](https://doi.org/10.1159/000514278)]
 - 39 **Kuo CH**, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C19 polymorphism influences Helicobacter pylori eradication. *World J Gastroenterol* 2014; **20**: 16029-16036 [PMID: [25473155](https://pubmed.ncbi.nlm.nih.gov/25473155/) DOI: [10.3748/wjg.v20.i43.16029](https://doi.org/10.3748/wjg.v20.i43.16029)]
 - 40 **Zhao X**, Zhang Z, Lu F, Xiong M, Jiang L, Tang K, Fu M, Wu Y, He B. Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis. *Front Pharmacol* 2022; **13**: 938419 [PMID: [36278195](https://pubmed.ncbi.nlm.nih.gov/36278195/) DOI: [10.3389/fphar.2022.938419](https://doi.org/10.3389/fphar.2022.938419)]
 - 41 **Kagami T**, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. *Aliment Pharmacol Ther* 2016; **43**: 1048-1059 [PMID: [26991399](https://pubmed.ncbi.nlm.nih.gov/26991399/) DOI: [10.1111/apt.13588](https://doi.org/10.1111/apt.13588)]
 - 42 **Shinozaki S**, Kobayashi Y, Osawa H, Sakamoto H, Hayashi Y, Lefor AK, Yamamoto H. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis. *Digestion* 2021; **102**:

- 319-325 [PMID: 31914442 DOI: 10.1159/000504939]
- 43 **Lyu QJ**, Pu QH, Zhong XF, Zhang J. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for *Helicobacter pylori* Eradication: A Meta-Analysis of Randomized Clinical Trials. *Biomed Res Int* 2019; **2019**: 9781212 [PMID: 31211144 DOI: 10.1155/2019/9781212]
- 44 **Maruyama M**, Tanaka N, Kubota D, Miyajima M, Kimura T, Tokutake K, Imai R, Fujisawa T, Mori H, Matsuda Y, Wada S, Horiuchi A, Kiyosawa K. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line *Helicobacter pylori* Eradication: A Randomized Controlled Trial. *Can J Gastroenterol Hepatol* 2017; **2017**: 4385161 [PMID: 28349044 DOI: 10.1155/2017/4385161]
- 45 **Suzuki S**, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. *Am J Gastroenterol* 2016; **111**: 949-956 [PMID: 27185079 DOI: 10.1038/ajg.2016.182]
- 46 **Zhang WL**, Lin BS, Li YY, Ding YM, Han ZX, Ji R. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for *Helicobacter pylori* Eradication: A Systematic Review and Meta-Analysis. *Digestion* 2023; **104**: 249-261 [PMID: 37015201 DOI: 10.1159/000529622]
- 47 **Senghor B**, Sokhna C, Ruimy R, Lagier JC. Gut microbiota diversity according to dietary habits and geographical provenance. *Human Microbiome J* 2018; **7-8**: 1-9 [DOI: 10.1016/j.humic.2018.01.001]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

